75098-42-9

Basic information

• Product Name: N-methylcyclopentanamine hydrochloride
• Synonyms: N-Cyclopentyl-N-methylamine hydrochloride;N-Methyl-cyclopentanamine HCl;N-methylcyclopentylamine HCl
• CAS NO: 75098-42-9
• Molecular Formula: C₆H₁₃N*ClH
• Molecular Weight: 136
• Mol File: 75098-42-9.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: N-methylcyclopentanamine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: N-methylcyclopentanamine hydrochloride(75098-42-9)
• EPA Substance Registry System: N-methylcyclopentanamine hydrochloride(75098-42-9)

Safety Data

• Hazardous Substances Data: 75098-42-9(Hazardous Substances Data)

Usage

General Description

N-methylcyclopentanamine hydrochloride is a chemical compound that consists of a cyclopentane ring with a methyl group and an amino group attached. It is commonly used as a reagent in organic synthesis and pharmaceutical research. The hydrochloride salt form of this compound is often preferred for its greater stability and solubility in water. In addition to its applications in chemical synthesis, N-methylcyclopentanamine hydrochloride also has potential pharmaceutical uses, particularly as an intermediate in the production of various drugs. It is important to handle this chemical with care as it can be hazardous if not properly managed.

Upstream product

• 67-56-1 methanol 
• 4254-02-8 cyclopentanecarbonitrile 
• 208245-79-8 tert-butyl cyclopentyl(methyl)carbamate 
• 593-51-1 methylamine hydrochloride 
• 120-92-3 cyclopentanone 
• 54915-64-9 ethyl cyclopentylcarbamate 
• 1003-03-8 Cyclopentamine 
• 41215-40-1 N-cyclopentylcarboxamide 

Downstream Products

• 1548298-83-4 N-cyclopentyl-N-methyl-4-(3-ureidophenyl)-1H-imidazole-1-carboxamide 
• 1201818-33-8 tert-butyl 4-{2-[3,5-dichloro-6-{[cyclopentyl(methyl)amino]methyl}-2-oxopyridin-1(2H)-yl]ethyl}benzoate 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS

The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.

UREA COMPOUNDS AND THEIR USE AS ENZYME INHIBITORS

A compound having the following structure: or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, Parkinson's disease, levodopa-induced dyskinesia, Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, Alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis.

Selective κ-opioid agonists: Synthesis and structure-activity relationships of piperidines incorporating an oxo-containing acyl group

This study describes the synthesis and the structure-activity relationships (SARs) of the (S)-(-)-enantiomers of a novel class of 2- (aminomethyl)piperidine derivatives, using κ-opioid binding affinity and antinociceptive potency as the indices of biological activity. Compounds incorporating the 1-tetralon-6-ylacetyl residue (30 and 34-45) demonstrated an in vivo antinociceptive activity greater than predicted on the basis of their κ-binding affinities. In particular, (2S)-2-[(dimethylamino)methyl]- 1-[(5,6,7,8-tetrahydro-5-oxo-2-naphthyl)acetyl]piperidine (34) was found to have a potency similar to spiradoline in animal models of antinociception after subcutaneous administration, with ED50s of 0.47 and 0.73 μmol/kg in the mouse and in the rat abdominal constriction tests, respectively. Further in vivo studies in mice and/or rats revealed that compound 34, compared to other selective κ-agonists, has a reduced propensity to cause a number of κ-related side effects, including locomotor impairment/sedation and diuresis, at antinociceptive doses. For example, it has an ED50 of 26.5 μmol/kg sc in the rat rotarod model, exhibiting a ratio of locomotor impairment/sedation vs analgesia of 36. Possible reasons for this differential activity and its clinical consequence are discussed.